Beam Therapeutics Inc. Q4 2025 Earnings Call Summary

Beam plans to utilize an 'umbrella' clinical trial design, allowing multiple mutation-specific base editors to be developed ...
GEN - Genetic Engineering and Biotechnology News

Beam Designs New Approach for Direct Correction of Mutations Causing PKU

Beam is advancing BEAM-304 using an approach in which multiple mutation-specific base editors are developed within a single clinical program.

Beam Therapeutics to Host Investor Webcast for Fourth Quarter and Year-End 2025 Financial Results and New Liver-targeted Genetic Disease Program

Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will announce its fourth quarter and full ...

Analyst bullish on Beam Therapeutics (BEAM) over drug program trajectory

Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the 13 hot stocks to buy with the highest upside potential. On February 9, ...
The Manila Times

Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)

New Program Designed as Platform-based Approach for Direct Correction of Mutations Causing PKU; Investigational New Drug (IND) Filing for BEAM‑304 Anticipated in 2026 ...